- £170.28bn
- £191.94bn
- $45.81bn
- 79
- 17
- 63
- 52
REG - AstraZeneca PLC - Dato-DXd NSQ NSCLC application withdrawn in EU
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in EU based on LAURA trial
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for limited-stage SCLC
AnnouncementREG - AstraZeneca PLC - AstraZeneca appoints Iskra Reic EVP International
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Truqap improved rPFS in advanced prostate cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Tagrisso recommended for EU approval - LAURA
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - KOMET Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - AstraZeneca invests $3.5 billion in US
AnnouncementREG - AstraZeneca PLC - Dato-DXd new BLA submitted, NSQ BLA withdrawn
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2024 Results
AnnouncementREG - AstraZeneca PLC - Tezspire nasal polyps trial met primary endpoints
AnnouncementREG - AstraZeneca PLC - AZN share price movement
Announcement